TP53 and neoplasm: A small clinical trial was conducted in nine non-small cell lung cancer (NSCLC) patients and found that bronchoscopic administration of the retroviral-WT p53-vector suppressed tumor growth and increased the presence of the TUNEL apoptosis marker at follow-up [111].